dr. mik rinne on the first promising cdk2 inhibitor in combination to treat hr /her2- breast cancer
Published 1 month ago • 77 plays • Length 5:47Download video MP4
Download video MP3
Similar videos
-
1:09:24
raising the bar in hr /her2- early breast cancer: cdk4 and 6 inhibitors
-
0:57
evaluating the benefits of selective cdk4 inhibition in hr /her2- breast cancer
-
6:35
first-in-human results of cdk2/4/6 inhibition in breast and ovarian cancer
-
7:40
cdk4/6 inhibitors in the first-line treatment setting
-
3:41
pf-07220060, a novel oral cdk4-selective inhibitor, in hr /her2- mbc
-
1:11
unmet needs in the use of cdk4/6 inhibitors in early-stage hr /her2- breast cancer
-
1:39
frontline endocrine therapies and ribociclib in early stage hr her2- breast cancer
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
8:55
cdk4/6 inhibitors in hr metastatic breast cancer
-
2:46
preliminary data on op-1250 palbociclib in advanced/metastatic er /her- breast cancer
-
7:23
study of ribociclib and pdr001 in hr metastatic breast cancer
-
2:26
cdk inhibitors in metastatic hormone-driven breast cancer
-
0:37
detecting breast cancer early
-
8:30
cdk4/6 inhibitors in er metastatic breast cancer during the covid-19 pandemic
-
5:32
first-line er-positive metastatic breast cancer treatments
-
0:16
clinical trials for breast cancer | william carter, md, facs
-
0:49
unmet needs for patients with prostate cancer
-
17:00
treatment of disease progression after first line cdk4/6 inhibitors by dr. omalkhair abulkhair